I am a proven scientific leader with comprehensive research skills in structure-based drug design, structural biology and biophysics. I have had a strong track record of contributing to the discovery of novel medicines such as Celebrex™, Bextra™, Dynastat™ and Deramaxx™ and to the advancement of over 15 clinical candidates. As a member of early stage drug discovery groups in Searle/Monsanto/Pharmacia/Pfizer, I had a strong penchant for tackling challenging scientific problems and consistently delivering results. I was one of the first crystallographers to solve a membrane protein structure in the pharmaceutical industry in the mid-90s. Over the years, my research interests have spanned proteases, protein kinases, hydrolases, nuclear hormone receptors, GPCRs, ion channelscyclooxygenases, cytochrome P450s and proteins involved in blood coagulation and fibrinolysis. I have broad experience in evaluation of kinase inhibitors for cardiovascular, inflammatory and neurological diseases. I am a co-author on over 80 scientific publications with >10,700 citations and an inventor on four patents. Since my retirement from Pfizer, working as an independent consultant, I have provided expert structural biology, biophysics and molecular mechanism of action consultancy services to startups and biotechs.